

---

## **LIFECORE BIOMEDICAL ANNOUNCES AGREEMENT WITH HYALOSE TO DISTRIBUTE HYALOSE'S NANO HA™, OLIGO HA™, AND SELECT HA™**

**CHASKA, MN. – July 22, 2009 – LIFECORE BIOMEDICAL, LLC** announced today that it has entered into a distribution agreement to market Hyalose L.L.C.'s line of hyaluronan research tools – Oligo-HA™, NanoHA™, Select HA™, Biotinylated Select HA™, and Hyalose Ladders. “Lifecore is pleased to be able to offer an expanded line of hyaluronan based biomaterials to the academic and corporate research communities through this distribution agreement, which nicely complements Lifecore’s offering of a broad range of molecular weights of pharmaceutical grade hyaluronan.”, said Dr. Kipling Thacker, VP of New Business Development for Lifecore. John Hoopingarner, President of Hyalose, added “This non-exclusive distribution agreement will now provide our hyaluronan to a broader research community of biologists, tissue and material engineers.”

Hyalose’s technology uses enzymatic digestion and controlled enzymatic synthesis that enables an exact determination of the hyaluronan output such as hyaluronan oligosaccharides or very narrowly distributed low to high molecular weight polymers. This processing also enables the placement of other glycosaminoglycan sugars at precisely defined positions in the polymer chain.

For more information on the Hyalose’s line of research tools, please contact Lifecore Biomedical at 952-368-6321 or by email at [Rebecca.Sebasky@lifecore.com](mailto:Rebecca.Sebasky@lifecore.com).

### **About Hyalose, L.L.C.**

Hyalose, L.L.C. is a biotechnology company founded on technology developed by Chief Scientists Paul DeAngelis, Ph.D. and Paul Weigel, Ph.D., at the University of Oklahoma Health Sciences Center. Hyalose has developed unique capabilities for the recombinant production of hyaluronic acid both in bulk production using fermentation and in enzymatic synthesis where a very high level of control is possible in determining the exact molecule that is synthesized. Controlled enzymatic synthesis also enables the placement of other glycosaminoglycan sugars and unnatural sugars at precisely defined positions in the sugar chain creating new novel sugar compounds. The company has licensed several genes from different species of bacteria that synthesize hyaluronic acid. Hyalose is funded and managed by life sciences venture firm, Emergent Technologies, Inc. For more information, visit the company website at [www.hyalose.com](http://www.hyalose.com).

### **About Lifecore Biomedical**

Lifecore Biomedical, LLC is a portfolio company of Warburg Pincus and has been in business over 40 years. It develops, manufactures, and markets hyaluronan based biomaterials and aseptically fills syringes and vials as medical devices and drugs for use in various human and veterinary markets.

News and general information are available through the Company’s website at [www.lifecore.com](http://www.lifecore.com) or by telephone at 952-368-4300.

CONTACT: 952-368-4300

Kipling Thacker, Ph.D., Vice President of New Business Development  
Rebecca Sebasky, New Business Development Associate

**- END -**